Recombinant human erythropoietin (r-HuEPO) is an established and effective therapy for anemia related to end stage renal disease.
In addition to its clinical effects, it has been associated with significant improvements in quality of life for anemic hemodialysis patients.
The therapy's impact on overall medical care expenditures for these patients remains uncertain, however.
In this study, we examine the costs of r-HuEPO as well as potential offsetting reductions in other medical care costs that might result from the therapy.
Mots-clés Pascal : Anémie, Hémopathie, Insuffisance rénale, Complication, Hémodialyse, Epuration extrarénale, Homme, Chimiothérapie, Traitement, Erythropoïétine, Appareil urinaire pathologie, Analyse avantage coût, Economie santé, Qualité vie, Canada, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Anemia, Hemopathy, Renal failure, Complication, Hemodialysis, Extrarenal dialysis, Human, Chemotherapy, Treatment, Erythropoietin, Urinary system disease, Cost benefit analysis, Health economy, Quality of life, Canada, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 92-0356123
Code Inist : 002B02G. Création : 199406.